Fludiazepam
| Clinical data | |
|---|---|
| Trade names | Erispan (JP, TW) |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets) |
| Drug class | Benzodiazepine |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.292.343 |
| Chemical and physical data | |
| Formula | C16H12ClFN2O |
| Molar mass | 302.73 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Fludiazepam, marketed under the brand name Erispan (エリスパン) is a potent benzodiazepine and 2ʹ-fluoro derivative of diazepam, originally developed by Hoffmann-La Roche in the 1960s. It is marketed in Japan and Taiwan. It exerts its pharmacological properties via enhancement of GABAergic inhibition. Fludiazepam has 4 times more binding affinity for benzodiazepine receptors than diazepam. It possesses anxiolytic, anticonvulsant, sedative, hypnotic and skeletal muscle relaxant properties. Fludiazepam has been used recreationally.